Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Sk°yen
0213 Oslo

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo

Tel:  +47 21 07 81 60

New search    Hide text from Guidelines


Antiseptic and antiinfective preparations for systemic use specifically used in urinary tract infections, see J01.
Antiinfectives for systemic use, see group J.
Gynecological antiinfectives and antiseptics, see G01.


This group comprises urological preparations other than antiseptics and antiinfectives.

G04BA Acidifiers
G04BC Urinary concrement solvents

This group comprises agents, which dissolve urinary concrements, e.g. citrates. Plain potassium citrate preparations indicated for e.g. treatment of renal tubular acidosis with calcium stones are classified in A12BA - Potassium (A12 Mineral supplements).

G04BD Drugs for urinary frequency and incontinence

This group comprises antispasmodics specifically used in the urogenital tractus.
Gastrointestinal antispasmodics, see A03.
Trospium in combination with analgesics are classified in A03DA.

The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.

G04BE Drugs used in erectile dysfunction

Alprostadil intracavernosal injection for treatment of erectil dysfunction is classified here, while formulations used to maintain the patency of the ductus arteriosis in neonates are classified in C01EA01.
Combinations of papaverine and phentolamine for intracavernous administration are classified under G04BE30 - combinations. Combinations of phentolamine and aviptadil (polypeptide) are classified under G04BE30 - combinations.
Phosphodisesterase inhibitors also indicated for pulmonary arterial hypertension (PAH) are classified in this group. Other agents used for treatment of PAH are classified in C02KX or in B01AC. Combinations of ambrisentan or macitentan and phosphodisesterase inhibitors are classified in C02KX - Antihypertensives for pulmonary arterial hypertension.
Combinations of alpha-adrenoreceptor antagonists or testosterone-5-alpha reductase inhibitors and phosphodisesterase inhibitors used in benign prostatic hypertrophy are classified in G04CA or G04CB, respectively.

The DDDs are based on single treatment of erectile dysfunction.

G04BX Other urologicals

This group comprises urologicals which cannot be classified in the preceding groups.
Phenazopyridine, plain products, are classified here, while phenazopyridine in combination with sulfonamides is classified according to the sulfonamide in J01EB20, J01EC20 or J01ED20.
Local anesthetic formulations for treatment of premature ejaculation are classified in N01B.

The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis. The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections. The other DDDs are based on the prophylaxis of urinary concrements.

Last updated: 2024-01-26